倾向性评分匹配证实:高级别浆液性卵巢癌初次手术与新辅助化疗生存相当
该回顾性队列研究利用单中心全部患者数据,采用倾向性评分、主成分分析和Cox比例风险分析比较匹配队列的生存。倾向性评分显示至少41%的晚期高级别浆液性癌患者中,新辅助化疗不劣于初次手术(中位生存:初次手术38个月,新辅助化疗35个月,P=0.39)。主成分分析结合Cox模型提示某些亚组(如膈下淋巴结病变)可能从初次手术中生存获益(HR 0.11,CI 0.026-0.48)。
要点
- 至少41%的晚期高级别浆液性癌患者中,新辅助化疗不劣于初次手术。
- 中位生存:初次手术38个月,新辅助化疗35个月,P=0.39。
- 膈下淋巴结病变患者初次手术可能生存获益(HR 0.11,CI 0.026-0.48)。
核心结论
- 既往试验结论可外推至更广泛人群,统计建模可识别从特定治疗方式获益的亚组。
研究设计与样本
- 单中心回顾性队列研究,纳入所有经治患者,采用倾向性评分分析、主成分分析和Cox比例风险分析比较匹配队列的生存。
主要发现
- 倾向性评分显示至少41%的晚期高级别浆液性癌患者中新辅助化疗不劣于初次手术(中位生存:初次手术38个月,新辅助化疗35个月,P=0.39)。
- 主成分分析结合Cox模型提示某些亚组(包括膈下淋巴结病变患者)初次手术可能生存获益(HR 0.11,CI 0.026-0.48)。
临床怎么用
- 对于晚期高级别浆液性卵巢癌,新辅助化疗可作为初次手术的等效选择,但膈下淋巴结病变等亚组可能需优先考虑初次手术。
局限性
- 回顾性单中心设计,统计建模结果需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our objective was to investigate whether trial evidence showing that neoadjuvant chemotherapy is non inferior to primary surgery for the primary treatment of advanced ovarian cancer could be extrapolated to groups of patients that were not included in the trials. METHODS: Using a detailed retrospective cohort of all patients managed through a single tertiary hospital we carried out a propensity score analysis, principal component analysis, and cox proportional hazard analysis to compare survival in matched cohorts. RESULTS: A propensity score analysis showed that for at least 41% of all patients with advanced high-grade serous cancer neoadjuvant chemotherapy is non inferior to primary surgery (median survival primary surgery: 38 months, neoadjuvant chemotherapy: 35 months. P = 0.39). However, principal component analysis, supported by cox modelling, suggests that for some subgroups, including patients with subdiaphragmatic nodal disease, primary surgery may be associated with improved survival (HR 0.11, CI 0.026-0.48). CONCLUSIONS: We have shown that the findings of previous trials can be extrapolated to a wider population and that statistical modelling can be used to identify groups or patients who benefit from specific modalities of treatment.
引用
- Russell B, Hawarden A, Gee M, et al. Propensity score matching confirms that primary surgery or neoadjuvant chemotherapy result in equivalent survival within a comprehensive cohort of patients with high-grade serous ovarian cancer. Gynecol Oncol. 2020. PMID: 33160693. doi:10.1016/j.ygyno.2020.10.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。